A GM-CSF knockdown T cell and its use
By co-expressing CAR structure and targeting shRNA in CAR-T cells, the expression of GM-CSF was reduced, and the toxic and side effects caused by excessive secretion of GM-CSF in CAR-T cell therapy were solved, and the prevention of toxicity was achieved The effect of side reactions, while maintaining the killing function of CAR-T cells, has high clinical application value.
Patent Information
- Application Number
- CN202010019264.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-01-08
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2040-01-08
AI Technical Summary
Excessive secretion of GM-CSF in CAR-T cell therapy leads to cytokine release syndrome and related encephalopathy syndrome. The existing technology methods are complex and increase the difficulty and cost of preparation, and the efficiency is uncertain, making it difficult to prevent these toxic and side effects. occur.
Design a GM-CSF knockdown chimeric antigen receptor expression vector, and realize co-expression of CAR structure and shRNA by combining short hairpin RNA (shRNA) expression frames targeting GM-CSF onto CAR expression vectors , synchronous expression of CAR and reduced expression levels of GM-CSF, T cells were transfected with this vector to prepare GM-CSF knockdown CAR-T cells.
Without increasing the burden of clinical medication and additional preparation procedures, the secretion level of GM-CSF is significantly reduced, preventing or reducing toxic and side effects related to cell therapy, maintaining the tumor killing function of CAR-T cells, and having high clinical practice Application value.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention relates to a genetically modified T cell, in particular to a GM-CSF knocked-down chimeric antigen receptor T cell and a use thereof, and belongs to the field of biopharmaceuticals. Background Art
[0002] Chimeric Antigen Receptor-T cells (CAR-T) therapy refers to an immunotherapy method that enables T cells to specifically target and kill tumor cells after genetic engineering. It can be used to treat relapsed and refractory malignant tumors of the blood system and other systems. The most widely used CAR-T cell therapy in clinical research and application is the use of anti-CD19-CART cells to treat relapsed and refractory CD19 + The total remission rate of B-cell malignancies can reach 50-90%, and some patients can achieve sustained disease remission. Novartis' Kymriah is the world's first approved CAR-T therapeutic product, used to treat acute lymphoblastic leukemia (ALL) in children and adolescents and relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults.
[0003] However, CAR-T cell therapy will have some characteristic side effects that are completely different from traditional chemotherapy and small molecule targeted drug therapy, which greatly affects the popularization and application of CAR-T cell therapy. The two most common side effects after CAR-T cell infusion include cytokine release syndrome (CRS, with the main symptoms of high fever, hypotension, hypoxia and / or multi-organ toxicity) and CART cell-related encephalopathy syndrome (CRES, mainly manifested as confusion, delirium, occasionally accompanied by epileptic seizures and cerebral edema). The incidence of these side effects ranges from 37% to 93%. Although they are controllable in most patients, a small number of patients require intensive care treatment, and a very small number of patients die as a result. Although there have been a large number of studies on the mechanism of toxic and side effects of cell therapy, the complete mechanism and prevention of CRS / CRES are still a scientific problem due to the complex interaction network between many immune cells and inflammatory factors. Therefore, it is necessary to trace the source of cytokine secretion to prevent the occurrence of CRS / CRES. At present, the IL-6 receptor blocking drug Tocilizumab is routinely used clinically to control CRS. If it is ineffective or neurotoxic reactions occur, glucocorticoids are recommended. However, the presence of toxic and side effects still inevitably increases the patient's medication burden and hospitalization time, requiring some patients to receive intensive care and treatment, and even causing uncontrollable toxic reactions in a few patients. Many clinical studies have found that in addition to IL-6, the inflammatory factors that are elevated in the serum of patients after infusion of CAR-T cells also include sIL-6R, sIL2Rα, IFN-γ, GM-CSF, MCP-1 and IL-1β. Studies have shown that after CAR-T cells contact and activate tumor cells, they first secrete proinflammatory cytokines such as GM-CSF and IFN-γ. These cytokines then contact immune cells such as monocytes, thereby prompting monocytes to secrete a large number of pathogenic inflammatory factors such as IL-6 and IL-1. It is reported that the secretion of IL-6 and IL-1 by myeloid cells induced by CAR-T is the main cause of CRS. GM-CSF secreted by CAR-T cells is the main factor for the activation of myeloid cells.
[0004] Some research teams have used TALEN or CRISPR / Cas9 technology to knock out the GM-CSF gene in CAR-T cells, thereby reducing GM-CSF secretion in CAR-T cells (2018, Sachdeva and Sterner). Their research results show that knocking out GM-CSF in CAR-T cells can prevent CRS reactions without damaging the function of CAR-T cells. However, the technical means they use require the prior electroporation of mRNA encoding the GM-CSF TALEN arm in T cells, or the additional transfection of lentivirus packaged with lentiCRISPRv2 plasmids while preparing CAR-T cells. These additional processes not only increase the difficulty and cost of preparation, but also damage the viability and growth capacity of CAR-T cells. In addition, the uncertainty of transfection efficiency also makes it difficult to predict the efficiency of GM-CSF knockdown. Therefore, we need a simpler and more effective technical means to prepare GM-CSF low-expressing CAR-T cells. Summary of the invention
[0005] In view of the shortcomings of the existing technology, we designed and constructed a new GM-CSF knockdown CAR expression vector, and combined the short hairpin RNA (shRNA) expression frame for knocking down GM-CSF into the CAR expression vector to achieve co-expression of CAR structure and shRNA. In this way, CAR is expressed synchronously and GM-CSF expression after CAR-T cell activation is reduced without increasing any medication burden and additional preparation process.
[0006] Specifically, the present invention provides a chimeric antigen receptor expression vector comprising
[0007] 1) at least one protein coding sequence encoding a chimeric antigen receptor, and
[0008] 2) at least one RNA coding sequence encoding an interfering RNA targeting human GM-CSF;
[0009] The interfering RNA is a shRNA targeting a sequence as shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4. Preferably, the RNA coding sequence comprises a sequence as shown in SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9. More preferably, the RNA coding sequence comprises a sequence as shown in SEQ ID NO: 9.
[0010] In a preferred embodiment, the chimeric antigen receptor targets CD19; more preferably, the protein coding sequence comprises the sequence shown in SEQ ID NO:23.
[0011] In another preferred embodiment, the promoter of the interfering RNA is the U6 promoter, and the promoter of the chimeric antigen receptor is the EF-1α promoter; preferably, the expression vector is pL-CAR+shRNA G1, pL-CAR+ shRNAG2, pL-CAR+shRNA G3, pL-CAR+shRNA G4; more preferably, the expression vector is pL-CAR+shRNA G4.
[0012] In a preferred embodiment, the expression vector is a lentiviral vector or an adenoviral vector, preferably a lentiviral vector, and more preferably an expression vector constructed based on the pWPXL plasmid.
[0013] Another aspect of the present invention provides the use of the above expression vector in preparing GM-CSF knockdown T cells, wherein the expression vector is transfected into the T cells. Preferably, the transfected T cells efficiently express chimeric antigen receptors, and the GM-CSF expression level is significantly lower than that of untransfected cells.
[0014] In another aspect, the present invention provides a GM-CSF knockdown T cell, wherein the T cell is transfected with any of the above expression vectors. Preferably, the T cell is a human peripheral blood mononuclear cell.
[0015] In a preferred embodiment, the expression efficiency of CD107a in the T cells is higher than 40%.
[0016] Another aspect of the present invention provides use of any of the above-mentioned T cells in the preparation of a drug for treating cancer; preferably, the cancer is leukemia, more preferably, the cancer is chronic myeloid leukemia or chronic lymphocytic leukemia.
[0017] Cell experiments have shown that the expression vector provided by the present invention can co-express the CAR structure and the shRNA that silences GM-CSF through a vector, and the tumor killing function of the GM-CSF knockdown CAR-T cells obtained after transformation using the expression vector is not impaired, and the secreted GM-CSF level is significantly reduced. The GM-CSF knockdown CAR-T cells provided by the present invention can prevent / mitigate cell therapy-related toxic and side effects without increasing the burden of clinical medication and additional preparation processes, and therefore have high clinical application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 . Schematic diagram of the shRNA design of the present invention, showing the location of the shRNA target site on GM-CSF mRNA and the mechanism of shRNA silencing the GM-CSF gene.
[0019] Figure 2 . Schematic diagram of the CAR expression vector according to the present invention, showing the construction positions of shRNA and CAR in the pL-CAR+shRNA plasmid.
[0020] Figure 3 .Knockdown of GM-CSF expression does not reduce CD107a expression on CAR-T cells.
[0021] Figure 4 .Knockdown of GM-CSF expression does not reduce the tumor cell killing ability of CAR-T cells.
[0022] Figure 5 .The CAR expression vector according to the present invention can effectively knock down GM-CSF expression after transfection.
[0023] Figure 6 .Different shRNAs have different efficiencies in knocking down GM-CSF in CAR T cells.
[0024] Figure 7 .GM-CSF secretion levels of cells in each group after activation. DETAILED DESCRIPTION
[0025] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention relates.
[0026] Chimeric antigen receptor (CAR)
[0027] Chimeric antigen receptors are generally composed of an extracellular antigen recognition domain, a hinge region, a transmembrane region, a co-stimulatory domain, and an activation domain. The extracellular antigen recognition domain specifically binds to the target molecule expressed on the surface of the tumor cell and provides an activation signal to the T cell, mainly including a single chain variable fragment (scFv) or a single domain antibody. The intracellular domain usually includes a CD3ζ chain and one or more co-stimulatory domains such as CD28 and / or 4-1BB (CD137) to promote T cell activation. In the classic CAR, the scFv fragment of a monoclonal antibody that specifically recognizes a tumor antigen is implanted into a T cell. For example, a lentiviral or retroviral vector can be used to introduce a nucleic acid encoding a CAR into a T cell. In this way, a large number of T cells that specifically recognize a protein target can be generated.
[0028] Granulocyte-macrophage colony stimulating factor factor, GM-CSF)
[0029] GM-CSF is a cytokine derived from a variety of immune cells. Macrophages, T cells, mast cells, endothelial cells and fibroblasts can secrete GM-CSF. Functionally, GM-CSF can promote the differentiation of myeloid stem cells into common progenitor cells of the granulocyte system (including eosinophils, neutrophils), erythrocytes, megakaryocytes and monocytes. It has a stimulating effect on the proliferation and differentiation of myeloid stem cells into various types of mature granulocytes. The GM-CSF targeted by the shRNA of the present invention is human GM-CSF, GeneBank number: M11220.1.
[0030] Cytokine Release Syndrome (CRS)
[0031] Cytokine release syndrome is a comprehensive clinical disease caused by the release of inflammatory cytokines by immune cells in a short period of time. The occurrence of this syndrome is often manifested by fever, hypotension, hypoxia, and neurological symptoms. The occurrence of cytokine release syndrome is usually related to the action of certain cytokines.
[0032] T cells
[0033] T cells, also known as T lymphocytes, are composed of a group of heterogeneous lymphocytes. Because they differentiate and mature in the thymus, they are called T cells. During the embryonic and neonatal periods of the human body, a portion of pluripotent stem cells or pre-T cells in the bone marrow migrate to the thymus, differentiate and mature in the thymus, and form T cells with immune activity. After maturation, T cells circulate in the blood to the peripheral lymphoid organs, settle and reproduce in their respective established areas. After being activated by antigens, T cells differentiate and proliferate, produce effector cells, and exercise their immune functions. Immune effector cells generally refer to immune cells that participate in the removal of foreign antigens and the exercise of effector functions in immune responses. Lymphocytes are produced and matured in the lymphatic system, and have a variety of types of cells with immune response functions, including T cells, B cells, natural killer cells (NK), macrophages, etc. Lymphocytes are further preferably T cells.
[0034] sequence
[0035] The "sequence" of the present invention should be understood to include sequences that are substantially identical to the sequences of the present invention. The term "substantially identical sequence" refers to a sequence that has at least 80%, 83%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity between the two sequences after optimal alignment, such as using the GAP or BESTFIT program and using the default gap value, and has the same or similar function, or is a protein / nucleotide sequence with the same or similar function obtained by deletion, substitution or addition of one or more amino acids / nucleotides to the sequence.
[0036] Gene knockdown
[0037] Gene knockdown is a technique that uses small RNA to efficiently and specifically bind to and degrade mRNA in cells that contains sequences homologous to small RNA, thereby blocking the expression of target genes in cells. After mRNA is degraded, the cell shows a phenotype of target gene deletion.
[0038] Interfering RNA
[0039] Interfering RNA can generally include shRNA and siRNA, both of which can reduce protein expression at the RNA level. shRNA and siRNA lead to the reduction of target gene mRNA through similar mechanisms. The difference between the two is that siRNA can directly target the target gene without processing, while shRNA contains a neck loop structure. Generally, after being expressed in the nucleus, it is processed by intracellular proteins and transported to the cytoplasm. In the cytoplasm, shRNA binds to Dicer to remove the ring sequence, and then binds to RISC and removes one of the RNA chains, and finally recognizes the target gene mRNA, leading to the degradation of mRNA.
[0040] Human peripheral blood mononuclear cells
[0041] Peripheral blood mononuclear cells (PBMCs) refer to cells with a single nucleus that exist in peripheral blood, including two major categories: lymphocytes and monocytes.
[0042] Expression vector
[0043] An expression vector is a type of vector that adds expression elements such as promoters and terminators to the basic skeleton of a DNA vector to enable the expression of the target gene on the vector. Another name for an expression vector is a plasmid. The chimeric antigen receptor expression vector of the present invention can be a lentiviral expression vector or an adenoviral expression vector.
[0044] Lentiviral vectors
[0045] Lentiviral vectors are a type of DNA vector containing lentiviral elements. Lentiviral vectors and lentiviral packaging plasmids are generally modified from HIV-1, and the two can be used together to prepare lentivirus. After infecting the target cell, the lentivirus carrying the target gene inserts the target gene into the target cell genome, so that the target cell stably expresses the target gene. The expression vector of the present invention is preferably a lentiviral vector, and more preferably an expression vector constructed based on the pWPXL plasmid.
[0046] cancer
[0047] The term "cancer" refers to a large class of various diseases characterized by the uncontrolled growth of abnormal cells in the body. Uncontrolled cell division and growth lead to the formation of malignant tumors or cells, which invade adjacent tissues and can also metastasize to distant parts of the body through the lymphatic system or bloodstream. Another equivalent description of "treating cancer" in the present invention is "treating tumors" or "anti-cancer" or "anti-tumor".
[0048] Cancer is a disorder of uncontrolled cell growth that interferes with the normal function of the body's organs and systems. A subject with cancer is a subject with objectively measurable cancer cells present in the subject's body. A subject at risk of developing cancer is a subject susceptible to developing cancer (e.g., based on family history, genetic predisposition), a subject exposed to radiation or other agents that cause cancer.
[0049] The T cells of the present invention can be used to prevent or treat a variety of cancers. Examples of such cancers may include breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, skin cancer, melanoma, colon cancer, stomach cancer, liver cancer, esophageal cancer, kidney cancer, pharyngeal cancer, thyroid cancer, pancreatic cancer, testicular cancer, brain cancer, bone cancer and blood cancer (such as leukemia, chronic lymphocytic leukemia), etc. Preferably, the GM-CSF knockdown T cells of the present invention can be used to treat human chronic myeloid leukemia or chronic lymphocytic leukemia.
[0050] The present invention will be further described below with examples. These examples are only used for illustration and do not constitute any limitation to the scope of the present invention. The abbreviations have the following meanings: "h" refers to hour, "min" refers to minute, "s" refers to second, "ms" refers to millisecond, "d" refers to day, "μL" refers to microliter, "mL" refers to milliliter, "L" refers to liter, "bp" refers to base pair, "mM" refers to millimole, and "μM" refers to micromole.
[0051] Example 1: Construction of GM-CSF knockdown CAR expression vector
[0052] 1. GM-CSF shRNA Design
[0053] The shRNA design tool (www.sigmaaldrich.com) was used to search for available shRNA sequence information targeting GM-CSF. The BLAST tool (https: / / blast.ncbi.nlm.nih.gov / Blast.cgi) was used for sequence alignment. The target site with the lowest off-target effect was selected. A total of 4 target sites (shRNA T1, shRNA T2, shRNA T3, and shRNA T4) and 1 control target site (shRNA T0) were selected. The shRNA target site sequences are shown in Table 1. Stem-loop structures and restriction sites (EcoR1 and BamH1) were designed for specific target sites to obtain the oligonucleotide sequences of shRNA. A total of four pairs of shRNAs (shRNA G1, shRNA G2, shRNA G3, and shRNA G4) were designed. At the same time, a non-specific control shRNA (shRNA G0) was designed. The specific shRNA sequences are shown in Table 2. The primers required for synthesizing shRNA are shown in Table 3 (shRNA primers were synthesized by Boshang Biotechnology (Shanghai) Co., Ltd.). The locations of the various shRNA target sites on GM-CSF mRNA and the mechanism of shRNA silencing of the GM-CSF gene are shown in Figure 1 .
[0054] Table 1. GM-CSF shRNA target site DNA sequences
[0055] Sequence number Target site name Target site DNA sequence SEQ ID NO: 1 shRNA T1 GAGATGAATGAAACAGTAGAA SEQ ID NO: 2 shRNA T2 GAAGTCATCTCAGAAATGTTT SEQ ID NO: 3 shRNA T3 GAAGGACTTTCTGCTTGTCAT SEQ ID NO: 4 shRNA T4 GGAGCTGCTCTCTCATGAAAC SEQ ID NO: 5 shRNA T0 AGCGTGTAGCTAGCAGAGG
[0056] Table 2. DNA sequence of GM-CSF shRNA
[0057]
[0058] Table 3. Primer list
[0059]
[0060]
[0061] 2. Construction of GM-CSF-shRNA expression cassette plasmid
[0062] 1) Dilute the shRNA primer to be annealed to 50 μM with triple distilled water. Add various reagents in sequence according to the following annealing reaction system and mix well.
[0063] Annealing reaction system:
[0064]
[0065] Set up the PCR instrument for annealing reaction, the reaction conditions are as follows: 95℃ for 2 minutes, decrease 0.1℃ every 8 seconds to 25℃, and keep at 4℃ for a long time. Dilute the annealing product 100 times for later use.
[0066] 2) Plvx-shRNA1 (Clontech) plasmid was digested with EcoRI (Thermo Scientific, #00565402) and BamHI (Thermo Scientific, #00566125) and then loaded onto 1% agarose gel. Electrophoresis was performed at 130V for 30 minutes. The gel was cut to recover the digestion product bands to obtain the purified digestion product. The purified digestion product was connected to the annealed product. The connection system was as follows:
[0067]
[0068] Add enzyme-free water to 20 μl and place in a 24°C water bath for 1 hour.
[0069] After the ligation was completed, the ligation product was transformed into DH5a competent cells (Tiangen Biochemical Technology, #CB101), and 200 μl of the transformation product was spread on LB agar plates with ampicillin resistance. After overnight at 37°C, single clones were picked and shaken and sent to Platinum Biotechnology (Shanghai) Co., Ltd. for sequencing. The consistent plasmids were used for subsequent experiments. The successfully constructed plasmids containing the GM-CSF-shRNA expression frame were numbered Plvx-shRNA1-G1, Plvx-shRNA1-G2, Plvx-shRNA1-G3, Plvx-shRNA1-G4 and Plvx-shRNA1-G0.
[0070] 3. Construction of GM-CSF-shRNA and CAR co-expression lentiviral vector
[0071] The shRNA expression cassette was obtained by PCR amplification from the U6 promoter-shRNA region of Plvx-shRNA1-G0 (target sequence: SEQ ID NO: 5) and Plvx-shRNA1-G4 plasmids (target sequence: SEQID NO: 4), with the amplification primers being SalI-F (SEQ ID NO: 21) and SalI-R (SEQ ID NO: 22), and the primers being provided with a SalI restriction site.
[0072] The antiCD19-CAR gene was synthesized by GenScript Biotech and cloned into the pUC57 vector (GenScript Biotech). The antiCD19-CAR DNA sequence and protein sequence are shown in Table 4 (SEQ ID NO: 23 and SEQ ID NO: 24). When synthesizing the gene, the restriction sites BamH1 and Nde1 were added at both ends of the gene. The antiCD19-CAR gene fragment was digested with restriction endonucleases and connected to the modified lentiviral vector (pWPXL, Addgene: 12257) to prepare a CAR lentiviral vector named pL-CAR. The successfully constructed plasmid was then digested with SalI (Thermo Scientific, #ER1021) and the digestion product was purified, and the shRNA expression frame amplified by PCR was connected to pL-CAR. The ligation and transformation operations were performed as described above to obtain lentiviral vector plasmids with both CAR expression frame and GM-CSF shRNA or control shRNA expression frame, which were named pL-CAR+shRNA G1, pL-CAR+shRNA G2, pL-CAR+shRNA G3, pL-CAR+shRNA G4 and pL-CAR+shRNA G0, respectively. The Qiagen HiSpeed Plasmid Maxi Kit (#12662) was used to extract the plasmid according to the experimental procedures provided in the kit for subsequent preparation of CAR-T cells.
[0073] Table 4. AntiCD19-CAR sequence list
[0074]
[0075]
[0076] Example 2: Different shRNAs have different efficiencies in knocking down GM-CSF in K562 cells
[0077] 2.1 Preparation of lentivirus containing shRNA
[0078] One day in advance, seed 293T cells at a rate of approximately 1 × 10 6 / well (4 ml DMEM complete medium) inoculate cells into 6-well plates. When the cell density reaches 90-95%, perform plasmid transfection. Aspirate and discard the original culture medium and replace it with serum-reduced OPTI-MEM culture medium.
[0079] First, prepare the plasmid complex: add the following plasmids to 375ul Opti-MEM (Thermo Fisher Scientific; 31985-070) and mix well: psPAX2 plasmid (Addgene; Catalog No.: 12260) 2.8125ug, pMD2.G plasmid (Addgene; Catalog No.: 12259) 0.9375ug, lentiviral vector plasmid (Plvx-shRNA1-G1, Plvx-shRNA1- G2, Plvx-shRNA1-G3, Plvx-shRNA1-G4 and Plvx-shRNA1-G0) 4ug, P3000 15ul.
[0080] Prepare the transfection reagent complex: add 22.5ul Lipofectamine 3000 (Invitrogen; 11668-019) to 375ul Opti-MEM, mix well, and let stand at room temperature for 5 minutes.
[0081] Add the plasmid complex to the transfection reagent complex, mix well and let stand for 25 minutes; finally, add the transfection complex to the cell culture medium and shake gently. Transfer to a 37°C cell culture incubator with 5% CO2. Collect the supernatant 48 hours after transfection, centrifuge at 3000rpm for 10 minutes to remove cell debris, and filter with a 0.45um filter membrane. Transfer the filtrate to a special centrifuge tube, balance it, and use an ultracentrifuge at 20000rpm for 2-3 hours. Pour out the supernatant, resuspend the lentivirus in serum-free culture medium, and store it at -80°C for later use after aliquoting. According to this process, prepare lentivirus containing shRNA G0, shRNA G1, shRNA G2, shRNA G3 and shRNA G1 respectively.
[0082] 2.2 Knockout of GM-CSF in K562 cells
[0083] K562 cells (human chronic myeloid leukemia cells) with good growth status were taken and cultured at 5×10 5 The cells were inoculated into 12-well plates and divided into six groups: untransfected cells, shRNA1-G1, shRNA1-G2, shRNA1-G3, shRNA1-G4 and shRNA1-G0. 600ul of the corresponding lentiviral supernatant, 400ul of RPMI 1640 complete medium and 1ul of polybrene (Yisheng, #40804ES76) were added to each group, and centrifuged at 1200g for 1.5 hours at 32°C. After 6 hours, the medium was replaced by centrifugation and complete medium was added. After 48 hours, the GFP expression of the cells was detected by flow cytometry to determine the transfection efficiency. After 72 hours, the cells were collected to extract proteins.
[0084] Protein extraction and Western blotting
[0085] 1. Protein extraction: Select 1X protein lysis and loading buffer (New Cyme, #WB2010), add protease inhibitor mixture (New Cyme, #P001) before use, collect cells by centrifugation, and wash once with PBS. Add lysis buffer to the cells collected in the 12-well plate at a ratio of 100ul / well, and vortex on a vortex oscillator until there is no obvious cell precipitation to fully lyse the cells. Heat in a 100℃ boiling water bath for 5-10 minutes, centrifuge at 12000rpm at 4℃ for 15 minutes, collect the supernatant, and store at -80℃ after aliquoting.
[0086] 2. Electrophoresis: Dissolve each pack of Tris-MOPS-SDS electrophoresis buffer powder (GenScript, #:M00138) in 1L of deionized water to make 1× electrophoresis buffer. Take out an appropriate volume of protein sample, heat it in a 100℃ water bath for 3-5 minutes to fully denature the protein, and after cooling to room temperature, load 10-25ul per well into the ExpressPlus TM Precast gel (GenScript, #M81615C) was loaded into the sample wells and electrophoresed at 140V for 50 minutes until the bromophenol blue band reached the bottom of the gel.
[0087] 3. Transfer: Prepare 1000mL fast transfer buffer (1×): 100mL fast transfer buffer (10×) + 750mL deionized water + 150mL methanol. Take out the gel after electrophoresis and cut the gel according to the protein marker and band position, and place it on the filter paper soaked in the transfer solution for later use. Cut the PVDF membrane according to the size of the gel, pour about 5ml of PVDF membrane infiltration activation solution (Biyuntian, #P0021S) into the dish, and use flat-head tweezers to clamp the PVDF membrane and soak the membrane until it is uniform and translucent. After rinsing in the transfer solution for 10 seconds, assemble the transfer "sandwich", pour the transfer solution to the marked line, and place the transfer tank in an ice water bath. Transfer the membrane at 100V for 50min.
[0088] 4. Blocking and applying primary antibody: After transfer, wash the blot membrane in 1×TBST for 1-2 minutes, pour about 10 ml of QuickBlock TM Western blocking solution (Biyuntian, #P0252) was placed on a horizontal shaker for about 20 minutes. TM Anti-GM-CSF antibody (Abcam, ab9741) was diluted 1:1000 in Western primary antibody diluent (Biyuntian, #P0256) and incubated at 4°C overnight with shaking.
[0089] 5. Wash the membrane: wash 3 times in 1×TBST, 10 min each time; apply secondary antibody: QuickBlock TM The secondary antibody was diluted with Western secondary antibody diluent (Biyuntian, #P0258); washed three times in 1×TBST, 10 min each time; an ultrasensitive ECL chemiluminescence kit (Biyuntian, #P0018S) was used, added dropwise to the PVDF membrane, and developed with a LAS-4000 chemiluminescence instrument.
[0090] The development results show ( Figure 3 ), 72 hours after viral transfection (transfection efficiency greater than 90%), the protein expression level of GM-CSF in K562 cell line was detected by Western blotting experiment, and shRNA G0 group was used as control to exclude the interference of transfection and off-target effects on GM-CSF expression. The results showed that the expression of GM-CSF in shRNA G0 and shRNA G1 groups did not decrease significantly; the expression of GM-CSF in shRNA G2, shRNA G3, and shRNA G4 groups was significantly reduced, among which shRNA G4 had the most obvious knockdown effect. According to the research needs, shRNA G4 was selected to construct a GM-CSF knockdown CAR expression vector.
[0091] Example 3: Preparation of GM-CSF knockdown CAR lentivirus
[0092] One day in advance, seed 293T cells at a rate of approximately 1 × 10 6 / well (4 ml DMEM complete medium) inoculate cells into 6-well plates. When the cell density reaches 90-95%, perform plasmid transfection. Aspirate and discard the original culture medium and replace it with serum-reduced OPTI-MEM culture medium.
[0093] First, prepare the plasmid complex: add the following plasmids to 375ul Opti-MEM (Thermo Fisher Scientific; 31985-070) and mix well: psPAX2 plasmid (Addgene; Catalog No.: 12260) 2.8125ug, pMD2.G plasmid (Addgene; Catalog No.: 12259) 0.9375ug, lentiviral vector plasmid (pL-CAR+shRNA G0 / 1 / 2 / 3 / 4) 4ug, P3000 15ul.
[0094] Prepare the transfection reagent complex: add 22.5ul Lipofectamine 3000 (Invitrogen; 11668-019) to 375ul Opti-MEM, mix well, and let stand at room temperature for 5 minutes.
[0095] Add the plasmid complex to the transfection reagent complex, mix well and let stand for 25 minutes; finally, add the transfection complex to the cell culture medium and shake gently. Transfer to a 37°C cell culture incubator with 5% CO2. Collect the supernatant 48 hours after transfection, centrifuge at 3000rpm for 10 minutes to remove cell debris, and filter with a 0.45um filter membrane. Transfer the filtrate to a special centrifuge tube, balance it, and use an ultracentrifuge at 20000rpm for 2-3 hours. Pour out the supernatant, resuspend the lentivirus in serum-free culture medium, and store it at -80°C for later use after aliquoting. According to this process, prepare lentivirus containing CAR, CAR+shRNA G0, CAR+shRNA G1, CAR+shRNA G2, CAR+shRNA G3 and CAR+shRNA G1 respectively.
[0096] Example 4: Preparation of GM-CSF knockdown CAR-T cells
[0097] Human peripheral blood mononuclear cells (Miaotong Biotech) frozen in liquid nitrogen were taken and cultured in PRIME- The culture medium was supplemented with 100 IU / ml IL-2 (Stemcell technologies) in cell CDM (Irvine, #91154) culture medium. An equal proportion of anti-CD3 / CD28 magnetic beads (Gibco, #1132D) were added to stimulate the cells, and lentiviral transfection was performed 24 hours later. They were divided into three groups: CAR, CAR+shRNAG0, and CAR+shRNAG4, and untransfected T cells were set as controls. 72 hours after the addition of the lentivirus, a certain volume of cells was taken, fluorescently labeled CD19 protein (Acrobiosystems) was added, and incubated at 4 degrees for 30 minutes. After incubation, wash once with PBS. Then resuspend the cells with PBS, and detect the expression of CAR in the cells by flow cytometry. CAR T cells, CAR+shRNAG0 T cells, and CAR+shRNA G4 T cells were obtained.
[0098] The results showed that the CAR expression efficiency of CAR T cells, CAR+shRNA G0 T cells and CAR+shRNA G4 T cells were 42.5%, 44% and 43.6%, respectively, and all three groups of cells reached about 40%. Therefore, the expression of shRNA does not affect the expression efficiency of CAR (see Figure 4 ).
[0099] Example 5: Detection of GM-CSF knockdown CAR-T cell killing ability
[0100] 1. Detection of CD107a expression
[0101] Add 2 × 10 per well in a 24-well plate. 5 CAR-T cells and 4×10 5 Nalm-6 cells (acute human B lymphoid leukemia cells, cell bank of the Chinese Academy of Sciences), 15 μl CD107a-PE antibody (BD Biosciences; 555801) and 1:30,000 diluted BD GolgiSF (BD Biosciences; 554724), incubated at 37°C for 4 hours, and then T cells and tumor cells were labeled with flow cytometry antibodies against CD3 (BD Biosciences; 555335) and CD19 antibody (eBioscience, 11-0199-42), respectively. The expression of CD107a in T cells was detected by flow cytometry. The results showed that the expression of CD107a in CAR+shRNA G4 T cells was 57.2%, while the CD107a expression efficiency of CAR T cells and CAR+shRNAG0 T cells was about 40%. Therefore, knocking down GM-CSF expression does not reduce the expression of CD107a in CAR-T cells (see Figure 5 ). Since CD107a is an important indicator of T cell and NK cell activation and killing, it can be considered that knocking down GM-CSF expression does not impair the killing activity of CAR-T cells.
[0102] 2. Killing experiment
[0103] After CAR-T cells and Nalm-6 cells carrying luciferase-GFP were co-cultured for 12 hours at an effector-target ratio of 1:1, 0.5:1, and 0.25:1, D-luciferin (Thermo Scientific, 8829) was added as a luminescent substrate to detect bioluminescence. The conversion formula for calculating the killing efficiency is: killing efficiency = (fluorescence value of the experimental well - fluorescence value of the blank control well) / fluorescence value of the target cell control well × 100%. The results showed that the killing efficiency of CAR T cells, CAR+shRNAG0 T cells, and CAR+shRNA G4 T cells on tumor cells reached about 80% when the effector-target ratio was 1:1 (see Figure 6 ). Therefore, knocking down GM-CSF expression has no significant effect on the efficacy of CAR T cells in killing tumor cells.
[0104] Example 6: Detection of GM-CSF secretion by GM-CSF knockdown CAR T cells
[0105] The experiment was divided into three groups: CAR T cells, CAR+shRNAG0 T cells, and CAR+shRNA G4 T cells. 4×10 5 CAR-T cells and 4×105 Nalm-6 cells (CD19+) were incubated in a 37°C incubator with 5% CO2 for 16 hours and the supernatant was collected. The Human GM-CSF ELISA kit (Shenzhen Dakoway, #1117302) was used to detect the expression of GM-CSF in the supernatant according to the experimental procedure provided by the kit. The results showed that the level of GM-CSF secreted by CAR+ shRNA G4 T cells after activation was significantly lower than that of CAR T cells and CAR+shRNAG0 T cells (see Figure 7 ). The above results show that we prepared GM-CSF knockdown CAR-T cells, and the knockdown of GM-CSF did not affect the tumor killing activity of CAR-T.
[0106] While specific embodiments of the present invention have been described above for purposes of illustration, those skilled in the art will appreciate that numerous changes in detail may be made without departing from the invention as described in the claims.
[0107]
[0108]
[0109]
[0110]
[0111]
[0112]
[0113] Sequence Listing <110> Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine <120> A GM-CSF knockdown T cell and its use <130> P2020-0026 <160> twenty four <170> SIPOSequenceListing 1.0 <210> 1 <211> twenty one <212> DNA <213> Homo sapiens <400> 1 gagatgaatg aaacagtaga a 21 <210> 2 <211> twenty one <212> DNA <213> Homo sapiens <400> 2 gaagtcatct cagaaatgtt t 21 <210> 3 <211> twenty one <212> DNA <213> Homo sapiens <400> 3 gaaggacttt ctgcttgtca t 21 <210> 4 <211> twenty one <212> DNA <213> Homo sapiens <400> 4 ggagctgctc tctcatgaaa c 21 <210> 5 <211> 19 <212> DNA <213> Homo sapiens <400> 5 agcgtgtagc tagcagagg 19 <210> 6 <211> 57 <212> DNA <213> Artificial Sequence <400> 6 gagatgaatg aaacagtaga attcaagaga ttctactgtt tcattcatct ctttttt 57 <210> 7 <211> 57 <212> DNA <213> Artificial Sequence <400> 7 gaagtcatct cagaaatgtt tttcaagaga aaacatttct gagatgactt ctttttt 57 <210> 8 <211> 57 <212> DNA <213> Artificial Sequence <400> 8 gaaggacttt ctgcttgtca tttcaagaga atgacaagca gaaagtcctt ctttttt 57 <210> 9 <211> 57 <212> DNA <213> Artificial Sequence <400> 9 ggagctgctc tctcatgaaa cttcaagaga gtttcatgag agagcagctc ctttttt 57 <210> 10 <211> 59 <212> DNA <213> Artificial Sequence <400> 10 agcgtgtagc tagcagaggt tcaagagacc tctgctagct acacgctttt tttacgcgt 59 <210> 11 <211> 63 <212> DNA <213> Artificial Sequence <400> 11 gatccgagat gaatgaaaca gtagaattca agagattcta ctgtttcatt catctctttt 60 ttg 63 <210> 12 <211> 63 <212> DNA <213> Artificial Sequence <400> 12 aattcaaaaa agagatgaat gaaacagtag aatctcttga attctactgt ttcattcatc 60 tcg 63 <210> 13 <211> 63 <212> DNA <213> Artificial Sequence <400> 13 gatccgaagt catctcagaa atgtttttca agagaaaaca tttctgagat gacttctttt 60 ttg 63 <210> 14 <211> 63 <212> DNA <213> Artificial Sequence <400> 14 aattcaaaaa agaagtcatc tcagaaatgt tttctcttga aaaacatttc tgagatgact 60 tcg 63 <210> 15 <211> 63 <212> DNA <213> Artificial Sequence <400> 15 gatccgaagg actttctgct tgtcatttca agagaatgac aagcagaaag tccttctttt 60 ttg 63 <210> 16 <211> 63 <212> DNA <213> Artificial Sequence <400> 16 aattcaaaaa agaaggactt tctgcttgtc attctcttga aatgacaagc agaaagtcct 60 tcg 63 <210> 17 <211> 63 <212> DNA <213> Artificial Sequence <400> 17 gatccggagc tgctctctca tgaaacttca agagagtttc atgagagagc agctcctttt 60 ttg 63 <210> 18 <211> 63 <212> DNA <213> Artificial Sequence <400> 18 aattcaaaaa aggagctgct ctctcatgaa actctcttga agtttcatga gagagcagct 60 ccg 63 <210> 19 <211> 65 <212> DNA <213> Artificial Sequence <400> 19 gatccagcgt gtagctagca gaggttcaag agacctctgc tagctacacg ctttttttac 60 gcgtg 65 <210> 20 <211> 65 <212> DNA <213> Artificial Sequence <400> 20 aattcacgcg taaaaaaagc gtgtagctag cagaggtctc ttgaacctct gctagctaca 60 cgctg 65 <210> 21 <211> 34 <212> DNA <213> Artificial Sequence <400> 21 atgtcgactc gggtttatta cagggacagc agag 34 <210> 22 <211> 33 <212> DNA <213> Artificial Sequence <400> 22 atcagctgga actccatata tgggctatga act 33 <210> 23 <211> 1458 <212> DNA <213> Artificial Sequence <400> 23 atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60 ccggacatcc agatgacaca gactacatcc tccctgtctg cctctctggg agacagagtc 120 accatcagtt gcagggcaag tcaggacatt agtaaatatt taaattggta tcagcagaaa 180 ccagatggaa ctgttaaact cctgatctac catacatcaa gattacactc aggagtccca 240 tcaaggttca gtggcagtgg gtctggaaca gattattctc tcaccattag caacctggag 300 caagaagata ttgccactta cttttgccaa cagggtaata cgcttccgta cacgttcgga 360 ggggggacca agctggagat cacaggtggc ggtggctcgg gcggtggtgg gtcgggtggc 420 ggcggatctg aggtgaaact gcaggagtca ggacctggcc tggtggcgcc ctcacagagc 480 ctgtccgtca catgcactgt ctcaggggtc tcattacccg actatggtgt aagctggatt 540 cgccagcctc cacgaaaggg tctggagtgg ctgggagtaa tatggggtag tgaaaccaca 600 tactataatt cagctctcaa atccagactg accatcatca aggacaactc caagagccaa 660 gttttcttaa aaatgaacag tctgcaaact gatgacacag ccatttacta ctgtgccaaa 720 cattattact acggtggtag ctatgctatg gactactggg gccaaggaac ctcagtcacc 780 gtctcctcaa ccacgacgcc agcgccgcga ccaccaacac cggcgcccac catcgcgtcg 840 cagcccctgt ccctgcgcc agaggcgtgc cggccagcgg cggggggcgc agtgcacacg 900 agggggctgg acttcgcctg tgatatctac atctgggcgc ccttggccgg gacttgtggg 960 gtccttctcc tgtcactggt tatcaccctt tactgcaaac ggggcagaaa gaaactcctg 1020 tatatattca aacaaccatt tatgagacca gtacaaacta ctcaagagga agatggctgt 1080 agctgccgat ttccagaaga agaagaagga ggatgtgaac tgagagtgaa gttcagcagg 1140 agcgcagacg cccccgcgta caagcagggc cagaaccagc tctataacga gctcaatcta 1200 ggacgaagag aggagtacga tgttttggac aagagacgtg gccgggaccc tgagatgggg 1260 ggaaagccga gaaggaagaa ccctcaggaa ggcctgtaca atgaactgca gaaagataag 1320 atggcggagg cctacagtga gattgggatg aaaggcgagc gccggagggg caaggggcac 1380 gatggccttt accagggtct cagtacagcc accaaggaca cctacgacgc ccttcacatg 1440 caggccctgc cccctcgc 1458 <210> 24 <211> 486 <212> PRT <213> Artificial Sequence <400> 24 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu 20 25 30 Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln 35 40 45 Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr 50 55 60 Val Lys Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Val Pro 65 70 75 80 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile 85 90 95 Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly 100 105 110 Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu 130 135 140 Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser 145 150 155 160 Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly 165 170 175 Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly 180 185 190 Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser 195 200 205 Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys 210 215 220 Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys 225 230 235 240 His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly 245 250 255 Thr Ser Val Thr Val Ser Ser Thr Thr Thr Pro Ala Pro Arg Pro Pro 260 265 270 Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu 275 280 285 Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp 290 295 300 Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly 305 310 315 320 Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg 325 330 335 Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln 340 345 350 Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu 355 360 365 Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala 370 375 380 Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu 385 390 395 400 Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp 405 410 415 Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu 420 425 430 Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile 435 440 445 Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr 450 455 460 Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met 465 470 475 480 Gln Ala Leu Pro Pro Arg 485
Claims
1. A chimeric antigen receptor expression vector, characterized in that: Include 1) a protein coding sequence encoding a chimeric antigen receptor, wherein the chimeric antigen receptor targets CD19, and the protein coding sequence is as shown in SEQ ID NO: 23, and 2) an RNA coding sequence encoding an interfering RNA targeting human GM-CSF; The interfering RNA is a shRNA targeting the sequence shown in SEQ ID NO:4, and the RNA coding sequence is shown in SEQ ID NO:
9.
2. The expression vector according to claim 1, characterized in that The promoter of the interfering RNA is the U6 promoter, and the promoter of the chimeric antigen receptor is the EF-1α promoter.
3. The expression vector according to claim 1, characterized in that The vector is a lentiviral vector.
4. Use of the expression vector according to any one of claims 1 to 3 in preparing GM-CSF knockdown T cells, characterized in that The expression vector is transfected into the T cells.
5. A GM-CSF knockdown T cell, characterized in that: The T cells are transfected with the expression vector according to any one of claims 1 to 3.
6. The T cell according to claim 5, characterized in that The T cells are human peripheral blood mononuclear cells.
7. Use of the T cell according to claim 5 or 6 in the preparation of a drug for treating leukemia.
Citation Information
Patent Citations
Treatment of cancer using anti-CD19 chimeric antigen receptor
CN107075482A
Chimeric antigen receptor containing truncated CD20 molecules and lentiviral vector as well as application
CN108276498A
CD19-CAR-T (Chimeric Antigen Receptor T) cell interfering with IFN (interferon)-gama expression and application thereof
CN108753773A
CD19-CAR-T (Chimeric Antigen Receptor T) cell interfering with IL (interleukin)-6 expression and application thereof
CN108753774A
Recombinant expression vector and targeted T cells, and applications thereof
CN110257429A
